Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs

Figures & data

Table 1 Glycemic goals

American Diabetes Association and the European Association for the Study of Diabetes	HbA1c < 7.0%
American Association of Clinical Endocrinologists/American College of Endocrinology	HbA1c ≤ 6.5%

Figure 1 Molecular structures of insulin glargine and insulin detemir.

Figure 2 Pharmacodynamic profile of insulin detemir.

Duration of action, time to peak action (GIR_max), and overall effect (AUC_GIR/100). Data obtained from Plank et al.²⁰

DeaMKHamilton-WesslerMAderMAlbumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptakeDiabetes20025176276911872677

 PubMed Web of Science ®Google Scholar